Busso CS, Iwakuma T, Izumi T (2009) Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway. Oncogene 28, 1616-25 19219073

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K24-ub - APE1 (human) ▲

Modsite: LrtEPEAkkSkTAAk SwissProt Entrez-Gene Orthologous residues APE1 (human): K24‑ub, APE1 (mouse): K23‑ub, APE1 (rat): K23‑ub Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE1 (human) UBIQUITIN LIGASE MDM2 (human) UBIQUITIN LIGASE UBE2D1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) inhibition of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme, transfection of inactive enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes p53 (human) increase nutlin-3 decrease Downstream Regulation Effect of modification (function):  enzymatic activity, altered, protein degradation

K25-ub - APE1 (human) ▲

Modsite: rtEPEAkkSkTAAkk SwissProt Entrez-Gene Orthologous residues APE1 (human): K25‑ub, APE1 (mouse): K24‑ub, APE1 (rat): K24‑ub Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE1 (human) UBIQUITIN LIGASE UBE2D1 (human) UBIQUITIN LIGASE MDM2 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) inhibition of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme, transfection of inactive enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes p53 (human) increase nutlin-3 decrease Downstream Regulation Effect of modification (function):  enzymatic activity, altered, protein degradation

K27-ub - APE1 (human) ▲

Modsite: EPEAkkSkTAAkkND SwissProt Entrez-Gene Orthologous residues APE1 (human): K27‑ub, APE1 (mouse): K26‑ub, APE1 (rat): K26‑ub Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE2D1 (human) UBIQUITIN LIGASE MDM2 (human) UBIQUITIN LIGASE UBE1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) inhibition of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme, transfection of inactive enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes p53 (human) increase nutlin-3 decrease Downstream Regulation Effect of modification (function):  enzymatic activity, altered, protein degradation